SUPN Stock Forecast 2025-2026
Distance to SUPN Price Targets
SUPN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Supernus (SUPN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SUPN and similar high-potential opportunities.
Latest SUPN Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, SUPN has a neutral consensus with a median price target of $38.00 (ranging from $36.00 to $44.00). The overall analyst rating is Buy (7.6/10). Currently trading at $33.04, the median forecast implies a 15.0% upside. This outlook is supported by 2 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Amsellem at Piper Sandler, projecting a 33.2% upside. Conversely, the most conservative target is provided by Kristen Kluska at Cantor Fitzgerald, suggesting a 9.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SUPN Analyst Ratings
SUPN Price Target Range
Latest SUPN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SUPN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 26, 2025 | Cantor Fitzgerald | Kristen Kluska | Neutral | Reiterates | $36.00 |
| Feb 19, 2025 | Cantor Fitzgerald | Kristen Kluska | Neutral | Downgrade | $36.00 |
| Sep 11, 2024 | Piper Sandler | David Amsellem | Neutral | Downgrade | $36.00 |
| Feb 28, 2024 | Piper Sandler | David Amsellem | Overweight | Maintains | $41.00 |
| Nov 9, 2023 | Piper Sandler | David Amsellem | Overweight | Maintains | $43.00 |
| Oct 25, 2023 | Piper Sandler | David Amsellem | Overweight | Maintains | $42.00 |
| May 10, 2023 | Piper Sandler | David Amsellem | Overweight | Maintains | $46.00 |
| Jan 23, 2023 | Piper Sandler | David Amsellem | Overweight | Maintains | $47.00 |
| Aug 31, 2022 | Piper Sandler | David Amsellem | Overweight | Maintains | $38.00 |
| Apr 13, 2021 | Jefferies | David Steinberg | Buy | Upgrade | $40.00 |
| Jun 16, 2020 | Piper Sandler | David Amsellem | Overweight | Upgrade | $31.00 |
| Apr 16, 2020 | Stifel | Annabel Samimy | Hold | Maintains | $24.00 |
| Nov 7, 2019 | Stifel | Hold | Downgrade | $23.00 | |
| Nov 7, 2019 | Stifel Nicolaus | Hold | Downgrade | $0.00 | |
| Nov 6, 2019 | Jefferies | Hold | Downgrade | $0.00 | |
| Dec 17, 2018 | Mizuho | Irina Rivkind Koffler | Buy | Maintains | $63.00 |
| Nov 12, 2018 | B. Riley Securities | David Buck | Buy | Maintains | $65.00 |
| Nov 12, 2018 | B. Riley FBR | Buy | Maintains | $0.00 | |
| Sep 18, 2018 | Mizuho | Buy | Initiates | $0.00 | |
| Aug 9, 2018 | Jefferies | David Steinberg | Buy | Maintains | $58.00 |
Supernus Pharmaceuticals Inc. (SUPN) Competitors
The following stocks are similar to Supernus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Supernus Pharmaceuticals Inc. (SUPN) Financial Data
Supernus Pharmaceuticals Inc. has a market capitalization of $1.83B with a P/E ratio of 24.8x. The company generates $661.82M in trailing twelve-month revenue with a 11.2% profit margin.
Revenue growth is +6.0% quarter-over-quarter, while maintaining an operating margin of +11.2% and return on equity of +7.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Supernus Pharmaceuticals Inc. (SUPN) Business Model
About Supernus Pharmaceuticals Inc.
Develops treatments for central nervous system disorders.
Supernus Pharmaceuticals generates revenue through a mix of proprietary products and strategic partnerships, focusing specifically on the development and commercialization of medications for CNS disorders. Their portfolio includes therapies for conditions such as epilepsy, migraine, ADHD, and bipolar disorder, addressing significant unmet medical needs in these areas.
The company's strong commitment to research and development allows it to maintain a robust pipeline of innovative treatments. Supernus is recognized for its contributions to improving patient outcomes and quality of life, which positions it as a significant player in the pharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
674
CEO
Mr. Jack A. Khattar M.B.A.
Country
United States
IPO Year
2012
Website
www.supernus.comSupernus Pharmaceuticals Inc. (SUPN) Latest News & Analysis
Levi & Korsinsky is investigating Supernus Pharmaceuticals (NASDAQ:SUPN) for potential federal securities law violations following the failure of its SPN-820 study for treatment-resistant depression.
Supernus Pharmaceuticals faces potential legal issues due to a failed clinical trial, which could negatively impact stock performance and investor confidence.
Levi & Korsinsky is investigating Supernus Pharmaceuticals (NASDAQ: SUPN) for potential federal securities law violations after its SPN-820 study for depression failed to meet primary endpoints.
Supernus Pharmaceuticals' failed clinical trial and the investigation into potential securities law violations may lead to stock volatility, affecting investor confidence and share value.
Levi & Korsinsky is investigating Supernus Pharmaceuticals (NASDAQ: SUPN) for possible federal securities law violations after its SPN-820 study for depression failed to meet its primary endpoint.
The investigation into Supernus Pharmaceuticals for potential securities law violations and the failure of a key drug study could lead to stock volatility and impact investor confidence.
Levi & Korsinsky is investigating Supernus Pharmaceuticals (NASDAQ:SUPN) for potential federal securities law violations following the failure of its SPN-820 depression study to meet primary endpoints.
The investigation into Supernus Pharmaceuticals for potential securities law violations, alongside the failed study results, raises concerns about the company's credibility and stock value.
Levi & Korsinsky is investigating Supernus Pharmaceuticals (NASDAQ: SUPN) for potential federal securities law violations after its SPN-820 trial for treatment-resistant depression failed to meet primary endpoints.
The investigation into Supernus Pharmaceuticals for potential securities law violations, coupled with the failed drug trial, raises concerns about the company's future and stock value.
Levi & Korsinsky is investigating Supernus Pharmaceuticals (NASDAQ: SUPN) for potential federal securities law violations following the failure of its SPN-820 study for treatment-resistant depression.
The investigation into Supernus Pharmaceuticals for potential securities law violations, coupled with the failed Phase 2b study, raises concerns about the company's financial health and stock performance.
Frequently Asked Questions About SUPN Stock
What is Supernus Pharmaceuticals Inc.'s (SUPN) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Supernus Pharmaceuticals Inc. (SUPN) has a median price target of $38.00. The highest price target is $44.00 and the lowest is $36.00.
Is SUPN stock a good investment in 2025?
According to current analyst ratings, SUPN has 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $33.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SUPN stock?
Wall Street analysts predict SUPN stock could reach $38.00 in the next 12 months. This represents a 15.0% increase from the current price of $33.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Supernus Pharmaceuticals Inc.'s business model?
Supernus Pharmaceuticals generates revenue through a mix of proprietary products and strategic partnerships, focusing specifically on the development and commercialization of medications for CNS disorders. Their portfolio includes therapies for conditions such as epilepsy, migraine, ADHD, and bipolar disorder, addressing significant unmet medical needs in these areas.
What is the highest forecasted price for SUPN Supernus Pharmaceuticals Inc.?
The highest price target for SUPN is $44.00 from David Amsellem at Piper Sandler, which represents a 33.2% increase from the current price of $33.04.
What is the lowest forecasted price for SUPN Supernus Pharmaceuticals Inc.?
The lowest price target for SUPN is $36.00 from Kristen Kluska at Cantor Fitzgerald, which represents a 9.0% increase from the current price of $33.04.
What is the overall SUPN consensus from analysts for Supernus Pharmaceuticals Inc.?
The overall analyst consensus for SUPN is neutral. Out of 7 Wall Street analysts, 2 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $38.00.
How accurate are SUPN stock price projections?
Stock price projections, including those for Supernus Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
